The College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), and the Association for Molecular Pathology (AMP) announced today the open comment period for the revised 2018 evidence-based guideline, “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors.”
How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma
In a rare display of bipartisan agreement, Congress is getting serious about addressing China’s influence in key industries. This spring’s “TikTok ban” is the most
September 12, 2024